Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition: Moderate to Severe Active Rheumatoid Arthritis Interventions: Drug: HS628+MTX; Drug: Actemra +MTX Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arthritis | Clinical Trials | Methotrexate | Research | Rheumatoid Arthritis | Rheumatology